Northstar Goes Supernova: Troubled Brain Stimulation Firm Plans Liquidation
This article was originally published in The Gray Sheet
Executive Summary
The directors of Northstar Neuroscience, developer of the Renova cortical stimulation system, have elected to liquidate all assets and dissolve the company
You may also be interested in...
St. Jude Medical picks up Northstar assets
St. Jude Medical acquires intellectual property and non-cash assets of failed neurotech device firm Northstar Neuroscience for $2 million June 8. Northstar makes the Renova cortical stimulation system, for which it was trying to gain approval for stroke and depression. The stroke trial did not meet its endpoints and the firm was unable to raise needed cash to continue with the depression indication (1"The Gray Sheet" Jan. 12, 2009, p. 15). The technology will add to St. Jude's established neuromodulation business, with a current emphasis on pain management, but a clinical trial focus on deep brain stimulation for movement disorders and depression
St. Jude Medical picks up Northstar assets
St. Jude Medical acquires intellectual property and non-cash assets of failed neurotech device firm Northstar Neuroscience for $2 million June 8. Northstar makes the Renova cortical stimulation system, for which it was trying to gain approval for stroke and depression. The stroke trial did not meet its endpoints and the firm was unable to raise needed cash to continue with the depression indication (1"The Gray Sheet" Jan. 12, 2009, p. 15). The technology will add to St. Jude's established neuromodulation business, with a current emphasis on pain management, but a clinical trial focus on deep brain stimulation for movement disorders and depression
What Happens After the Device IPO?
Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?